This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

NeoStem To Present At Multiple Conferences In April

Stocks in this article: NBS

NEW YORK, April 1, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced that the Company and its subsidiary, Progenitor Cell Therapy ("PCT"), will present at multiple conferences in April.

Cancer Immunotherapy Conference: Stem Cells and Cancer Immunotherapy

  • Date and Time: Friday, April 5, 10:35 AM EDT
  • Venue: Washington Post Conference Center, Washington, DC
  • Session: Challenges and Solutions for the Commercial Manufacture of Immunomodulatory Cell Products
  • Speaker: Robert A. Preti, PhD, President and Chief Scientific Officer of PCT

Second International Vatican Adult Stem Cell Conference: Regenerative Medicine – A Fundamental Shift in Science and Culture

  • Dates: Thursday, April 11 to Saturday, April 13
  • Venue: Aula Nuova del Sinodo, Vatican City
  • Speakers: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem, Robert A. Preti, PhD, President and Chief Scientific Officer of PCT, Jonathan Sackner-Bernstein, M.D., FACC, Vice President of Clinical Development and Regulatory Affairs of NeoStem, and Catherine Vaczy, Esq., Vice President and General Counsel of NeoStem, will all present as part of the conference

CMC Workshop: From Drug Development to Global Supply to Patients

  • Date and Time: Wednesday April 17, 8:00 AM EDT
  • Venue: Washington Marriott Hotel, Washington, DC
  • Session: Advanced-Therapy Medicinal Products (ATMP)
  • Speaker: Robert A. Preti, PhD, President and Chief Scientific Officer of PCT

Regen Med and Advanced Therapies Investor Day

  • Date and Time: Wednesday April 17, 2:15 PM EDT
  • Venue: Harmonie Club, New York, NY
  • Speaker: Jonathan Sackner-Bernstein, M.D., FACC, Vice President of Clinical Development and Regulatory Affairs of NeoStem, will give a presentation on Amorcyte

AFUND Small Cap Opportunities Luncheon Symposium

  • Date and Time: Monday April 22, 12:00 PM EDT
  • Venue: Princeton Club, New York, NY
  • Speaker: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem, will give a company presentation

Stem Cell Research & Regenerative Medicine – 10 th Stem Cell Summit

  • Venue: Hyatt Regency Boston Hotel, Boston, MA
  • Session 1 Date and Time: Monday, April 29, 3:30 PM EDT
  • Session 1 Title: Commercialization: Bringing Therapeutics to Market
  • Session 1 Speaker: Robert A. Preti, PhD, President and Chief Scientific Officer of PCT
  • Session 2 Date and Time: Tuesday, April 30, 11:15 AM EDT
  • Session 2 Title: Advances in Adult Stem Cells
  • Session 2 Speaker: Jonathan Sackner-Bernstein, M.D., FACC, Vice President of Clinical Development and Regulatory Affairs of NeoStem

BIO International Convention – BioProcess Zone

  • Date and Time: Tuesday, April 23, 2:00 PM EDT
  • Venue: McCormick Convention Center, Chicago, IL
  • Session: Leveraging a CMO to optimize the financial and operational efficiency of an emerging cell therapy business
  • Speaker: Robert A. Preti, PhD, President and Chief Scientific Officer of PCT

About NeoStem, Inc.

NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization ("CDMO") providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts for cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: NeoStem
         Dr. Robin L. Smith
         Chairman and CEO
         Phone: +1-212-584-4174
         Email: rsmith@neostem.com

NeoStem Inc. Logo

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs